- NACDS RxImpact shines spotlight on pharmacists' increasing role in delivery of healthcare services
- Study: Diabetes prevalence has doubled in past 25 years
- Insurance rollout shows pharmacies and NACDS in action
- NACDS supports bill to curb Rx abuse, safeguard patients
- FDA approves liquid form of Merck HIV drug Isentress for infants, small children
WHITEHOUSE STATION, N.J. — The Food and Drug Administration has approved a drug made by Merck for Type 2 diabetes, the drug maker said Thursday.
Merck announced the approval of Janumet XR (sitagliptin and metformin hydrochloride) extended-release tablets as a once-daily treatment for the disease.
"Janumet XR is a new treatment that adds once-daily convenience to the powerful efficacy of Janumet for patients with Type 2 diabetes," Merck VP diabetes and endocrinology Barry Goldstein said. "This is important because many patients with Type 2 diabetes require treatment with multiple drugs to maintain blood-sugar control, and Janumet XR is a new option to help more patients get to their glucose goals."